> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# NeuroDerm Gains Access to Infusion Pumps Again
- URL: https://www.fdaweb.com/neuroderm-gains-access-to-infusion-pumps-again/
- Published: 2016-04-22T12:00:00.000Z
- Updated: 2026-09-14T20:56:50.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135473

> FDA has removed from its import alert NeuroDerm’s third-party manufacturer of infusion pumps used to deliver the investigational drug ND0612 in its current clinical trials. The alert was ordered on Can SpA’s devices 7/2015 after FDA sent it a Warning Letter requesting additional documentation pertaining to GMPs. The manufacturer’s corrective actions and response to the Warning Letter have now been determined by agency to be adequate, NeuroDerm says.  
>  
> NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system product candidates for treating Parkinson’s disease. It has developed a line of levodopa and carbidopa products that are intended to be administered through small belt pumps that deliver a continuous, controlled drug dose.